There is something to be said about "being first to market". UTHR has done an excellent job of building market share for drugs that combat PAH. Tyvaso DPI is considered a "next generation" Tyvaso, a marked improvement over the nebuliized Tyvaso, as I understand it. UTHR's sales force is highly developed, and presumably, "second to none" in the PAH market.

Even if Yutrepia has several redeeming qualities and the product might be differentiated, do they have the sales force expertise that UTHR has developed over the years? I don't see LQDA offering significant market competition in the near future, even if it comes to market in late 2023 or early 2024. JMHO.